Chen Sizhe, Qi Huitang, Zhu Xingzhuo, Liu Tianxiang, Fan Yuting, Su Qi, Gong Qiuyu, Jia Cangzhi, Liu Tian
MOE Key Laboratory of Bio-Intelligent Manufacturing, School of Bioengineering, Dalian University of Technology, Dalian, Liaoning, 116024, China.
Microbiota I-Center (MagIC), Hong Kong SAR, China.
Microbiome. 2024 Dec 21;12(1):272. doi: 10.1186/s40168-024-01985-9.
The overuse of antibiotics has led to lethal multi-antibiotic-resistant microorganisms around the globe, with restricted availability of novel antibiotics. Compared to conventional antibiotics, evolutionarily originated antimicrobial peptides (AMPs) are promising alternatives to address these issues. The gut microbiome of Blattella germanica represents a previously untapped resource of naturally evolving AMPs for developing antimicrobial agents.
Using the in-house designed tool "AMPidentifier," AMP candidates were mined from the gut microbiome of B. germanica, and their activities were validated both in vitro and in vivo. Among filtered candidates, AMP1, derived from the symbiotic microorganism Blattabacterium cuenoti, demonstrated broad-spectrum antibacterial activity, low cytotoxicity towards mammalian cells, and a lack of hemolytic effects. Mechanistic studies revealed that AMP1 rapidly permeates the bacterial cell and accumulates intracellularly, resulting in a gradual and mild depolarization of the cell membrane during the initial incubation period, suggesting minimal direct impact on membrane integrity. Furthermore, observations from fluorescence microscopy and scanning electron microscopy indicated abnormalities in bacterial binary fission and compromised cell structure. These findings led to the hypothesis that AMP1 may inhibit bacterial cell wall synthesis. Furthermore, AMP1 showed potent antibacterial and wound healing effects in mice, with comparable performances of vancomycin.
This study exemplifies an interdisciplinary approach to screening safe and effective AMPs from natural biological tissues, and our identified AMP 1 holds promising potential for clinical application.
抗生素的过度使用已在全球范围内导致具有致命性的多重耐药微生物出现,新型抗生素的可获得性也受到限制。与传统抗生素相比,进化产生的抗菌肽(AMPs)是解决这些问题的有前景的替代方案。德国小蠊的肠道微生物群是开发抗菌剂的天然进化抗菌肽的一个尚未开发的资源。
使用内部设计的工具“AMPidentifier”,从德国小蠊的肠道微生物群中挖掘出抗菌肽候选物,并在体外和体内验证了它们的活性。在筛选出的候选物中,源自共生微生物克氏blattabacterium的AMP1表现出广谱抗菌活性、对哺乳动物细胞的低细胞毒性以及无溶血作用。机制研究表明,AMP1能迅速穿透细菌细胞并在细胞内积累,在初始孵育期导致细胞膜逐渐且轻微的去极化,这表明对膜完整性的直接影响最小。此外,荧光显微镜和扫描电子显微镜的观察结果表明细菌二分裂异常且细胞结构受损。这些发现导致了一个假设,即AMP1可能抑制细菌细胞壁的合成。此外,AMP1在小鼠中显示出强大的抗菌和伤口愈合作用,与万古霉素的表现相当。
本研究例证了一种从天然生物组织中筛选安全有效抗菌肽的跨学科方法,我们鉴定出的AMP1在临床应用方面具有广阔的潜力。